3,052 karma · joined July 15, 2009
For example, in the 90s a lot of people thought everyone would host their own email servers. In reality, consumers flocked to Y! mail and later Gmail, since most people really can't or won't do this themselves.
Most people also do not change the oil on their own car (at least in the USA) etc.
In my mind the question is can you develop a great product in this area. It is possible (and sad) that Ring or Nest is as good as it gets (or have default won due to superior distribution). But I do think there are a lot of features I would want as a consumer that would make this experience better for me.
There are a lot of things that should exist but are harder to do: -Safe, cheap nuclear power -Longevity drugs (I am involved with two companies in that area) -Independent journalism school/foundation -Pioneer on steroids (how to identify and nurture the top global talent for every area of human endeavor) -Etc.
But that is perhaps another post / different topic?
What else would you add?
There are a lot of things that should exist but are harder to do: -Safe, cheap nuclear power -Longevity drugs (I am involved with two companies in that area) -Independent journalism school/foundation -Pioneer on steroids (how to identify and nurture the top global talent for every area of human endeavor) -Etc.
But that is perhaps another post / different topic.
Crypto has a lot of aspects that make for a superior store of value (easy to move, seizure and censorship proof etc). Obviously, also has some drawbacks too like difficulty to custody...
And then a set of markets I thought would be smaller or binary. Full post here: http://blog.eladgil.com/2015/01/hot-markets-for-2015.html
For genomics in particular, Illumina is now a $40 billion company while Exact Sciences ($9B), Invitae ($1 billion), 23andMe (a few billion) and Ancestry (a few billion) are all in the market too.
"Sometimes this creates a very backwards looking view, as the most obvious signals are in companies that have been working well for a few years and the trend is really over."
I do think DevOps is an exciting market with a lot going on. (I am an investor in GitLab, PagerDuty, and other related companies)...
Also, here is a blog I wrote on re-orgs: http://blog.eladgil.com/2018/04/how-to-do-re-org.html
There are some good things written on this topic that you have probably seen - e.g. Paul Graham has some great posts on this as do Sam Altman, Michael Seibel and Aaron Harris.
On the non-YC side Peter Thiel's Zero to One, Marc Andreessen's archives (on the A16Z site) and Chris Dixon's pre-crypto writings are all great on this topic too....
I think the two key things are to (1) spend time where hypersmart, slightly weird people are and (2) focus on markets with real (versus theoretical) needs...
The book does get into some of the other issues you mention in other sections. There are only a few pages about "managing in a downturn" (which is literally the name of a section later in the book).
I think when we finally end this long bull market run we have been in, there will be lots of pain (and lots of articles and blogs about what to do now that the sky is falling).
Thanks again for taking a look!
I think two sections might be most generically interesting or useful:
1. The interviews. There are 14 interviews with Sam Altman, Marc Andreessen, Patrick Collison, Joelle Emerson, Erin Fors, Reid Hoffman, Claire Hughes Johnson, Aaron Levie, Mariam Naficy, Keith Rabois, Naval Ravikant, Ruchi Sanghvi, Shannon Stubo Brayton, Hemant Taneja.
In some cases, their advice is at odds with my own. So I think the richness of perspectives and experiences are valuable.
2. The sections on executives, recruiting, people, onboarding, re-orgs, etc.
Startups are a team sport, and getting the right team together and helping them be effective is really the key (assuming you already have product/market fit).
A big part of that is also the role of the CEO, and the CEO managing their own psychology, not burning out, etc.
You can still order via Amazon - as of now it will just take a few extra days to ship. So not a huge delay if you are willing to wait.
While come technology companies (or retail, or other companies) are profitable from day 1, many instead chose to invest in growth early on to go for market share and win the market. They then hike prices, cross-sell product, or drop costs at scale and then spin off a ton of cash. In Silicon Valley these companies are usually funded by VCs. In other industries, they may have different types of loans or in some cases private equity, VC, or friends and family money.
In either case, the companies will share common issues - How do I add executives in functions I have never dealt with? E.g. a CFO or GC? How does my role as CEO evolve as the team grows and I am no longer needed to do the things I used to do when we were 5 people? Etc.
This book definitely has a Silicon Valley Tech bias, as that is what I know best. Anecdotally, I have been told by people in non-tech industries who saw an early copy that some of the "people-centric" chapters are more broadly relevant. But rapidly scaling technology companies will definitely benefit the most from it.
In terms of growing revenue and profits, I think a number of books focus on that. E.g. how to build a sales org, or compensate them, or different channel strategies. Those are really valuable topics but I felt they were better covered than some of the topics I focus on.
Thanks for taking a look! :)
Outside of financing and M&A, most of the topics in the book are core to most fast growing companies - Silicon Valley or not. They key is whether the company needs to grow rapidly, or is a rapidly growing division of a company. "Grow rapidly" means "scaling revenue (and if the right time for the company, profits), and growing headcount and organizational complexity". If it is a 12 person org that is not going to grow, only a smaller subset of topics apply.
Key topics include things like hiring and managing an executive team, your role as CEO, organizational topics (re-orgs, choosing what executive owns what etc.), marketing and PR, product management, managing your board, building a recruiting pipeline and recruiting organization. Many of these are reasonably universal topics. To your point, what I know best is silicon valley technology companies, and the book reflects that experience (versus that of an industrial company).
Thanks again for taking a look!
[Cost] In order to provide clinical results in a CAP/CLIA environment we need to ensure sufficient coverage to call all SNV/indels and all CNVs. This means we need much higher average coverage then 30X.
Since your exome is just 1-2% of your genome, and your exome encodes 20,000 to 25,000 genes, this means that 30 genes is <1% of your exome which itself is just <2% of your genome. So the Illumina sequencing costs of 30 genes alone are on the order of a fraction of a percent of the cost of doing whole genome (assuming you are using the same machines and the same coverage).
Now, there are some caveats to this, e.g.: -You would use a slower, higher output more expensive machine like an X10 to do a whole genome at scale. -You can save some costs by doing whole genome versus a targeted panel as the pulldown step of the panel adds additional unique costs of its own. -This does not include fixed costs of sample collection, or secondary confirmation, or other costs that increase the price per test. This does not include labor costs, bioinformatics, or other items where sometimes dealing with a whole genome is cheaper per bp of DNA then doing a smaller panel of genes. -I think the "$1000 genome" isn't really here yet.
In a few years, the cost of sequencing the whole genome will be a few hundred dollars, at which point I think it makes sense to do the whole thing.
[Usefulness] It is important to note, however, that most of the genome is not very actionable right now. At Color our focus is on providing you with information you and your doctor can use, which means most of your genome is not characterized well enough to be clinically useful. At this point, depending on who is doing the estimate, only 30-60% of the 20,000+ genes you have are ascribed to a function, and even then it is often unclear how impactful a mutation in those genes are....
Color is focused on testing for characterized genes (e.g. BRCA1, BRCA2, PTEN, etc.) which have an impact to an individuals risk of developing cancer. Environmental and other factors of course play a role, and most cancers are not caused by these genes. However, knowing that you are at high risk of developing cancer is something a patient can work on with their physician to develop a personalized screening and prevention plan. For example, national guidelines from NCCN suggest that women with a BRCA1 mutation get more frequent mammograms. See also cancer.gov risks for having a BRCA1 or BRCA2 mutation: https://www.cancer.gov/about-cancer/causes-prevention/geneti...
Color was developed working closely with some of the leading cancer researchers including Dr. Mary-Claire King, who is credited with discovering BCRA1, and Dr. Laura Esserman and Dr. Laura v'ant Veer at UCSF. Our team includes people with backgrounds in genetics, medicine, and clinical pathology as well as machine learning, big data, and systems engineering.
This unique combination of skills is really crucial to pushing this area forward. For example, the Komen Foundation (one of the world's biggest breast cancer foundation) held a conference I was part of the planning committee for at Rockefeller University last year on big data for breast cancer. http://ww5.komen.org/BD4BC.html
Marrying data science to medicine is a way to drive cancer research forward.
As an aside, one of Color's founders is a BRCA carriers whose mother had breast cancer twice, and whose grandmother died of the disease. So, it is a bit sad to me that the default assumption is we are "academic imperialists" versus people trying to do something good for the world.
Thanks for reading :)
There are some circumstances where in a big acquisition like this founders or key employees are asked to re-start the vesting clock on their shares. This is more common in small buys but can happen in big ones too. In this case you get some payout for e.g. the 2 years you were there and then the rest of your stock (and maybe a refresher) get spread over 3 or 4 years.
In terms of payout, if you assume by series C that 50-75% of the company was sold to investors then $1.5B to $2.25B will go to investors and the remaining 750 million to $1.5 billion goes to founders and employees. Obviously this is a huge range and you need the cap table to know what really happened.
Experienced frontend, backend, full stack, and data engineers. https://getcolor.com/careers
Build the software infrastructure for genetics and genomics.
Genetics is at the beginning of a large growth trajectory. Color has the opportunity to build the software infrastructure that will drive the entire field. From data analytics to bioinformatics and product design, you will be part of implementing the first truly large-scale application of genetics.
We are looking for smart collaborative individuals with a tech background and interest in the area versus people with deep domain expertise.
We are just a few minutes walk from both Caltrain and BART.